Becton Dickinson and Company (BDX)

3 Large-Cap Stocks with Questionable Fundamentals

3 Profitable Stocks We Steer Clear Of

While Solventum has lagged behind the broader Dow Jones Industrial Average, analysts remain optimistic about the stock.

Baxter has notably underperformed the Medical Devices industry over the past year, and analysts are cautious about the stock’s prospects.

3 Reasons BDX is Risky and 1 Stock to Buy Instead

3 Healthcare Stocks Walking a Fine Line

The first and only innovation of its kind to receive 510(k) clearance, Surgiphor™ 1000mL empowers surgical teams with a consistent, antimicrobial solution designed to improve patient care and operating...

As Becton, Dickinson and Company has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

Despite Stryker’s underperformance relative to its peers over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

FRANKLIN LAKES, N.J. , Feb. 25, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) (the " Company " or " BD "), a leading global medical technology company, today announced...